Biotech | October 21, 2021
Sage Therapeutics and Biogen plan to submit a New Drug Application (NDA) for zuranolone
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
